ELSEVIER
SAUNDERS

Immunol Allergy Clin N Am
25 (2005) 757–780

IMMUNOLOGY
AND ALLERGY
CLINICS
OF NORTH AMERICA

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

A Disintegrin And Metalloproteinase gene. *See ADAM33* gene.

Abdominal pain, in exercise-induced asthma, 34

Acetaminophen, asthma induced by, 177

Acetylsalicylic acid. *See* Aspirin.

Acne, corticosteroid-induced, 575

ACTH (adrenocorticotropic hormone), in cortisol regulation, 559

Activator protein-1, glucocorticoid receptor interaction with, 463

ADAM33 gene, in asthma, **655–668**
- beta-variant of, 662
- candidate gene analysis of, 690–692
- identification of, 656
- in origin, 663–664
- mechanistic role of, 657–659
- meta-analysis of, 657
- polymorphisms of, 661
- prodomain of, 659–661
- replication of, 656–657
- severe, 663
- soluble form of, 660, 662
- structure of, 658
- S-variant of, 662
- tissue expression of, 659–663
- versus other *ADAM* genes, 658–659, 662

Adenoidectomy, for rhinosinusitis, 327

Adenosine, in exercise-induced asthma, 33

Adenovirus infections, asthma in, 47–48, 51–52

Adherence, in corticosteroid therapy, **581–595**
- overview of, 582
- problems with
  - barriers, 584–586
  - Internet information, 589–591
  - mass media role in, 587–589
  - reasons for, 582–583
  - steroid phobia, 583–584, 591–593

ADRβ2 gene, in asthma, beta agonists and, 727–731

Adrenal gland. *See also* Hypothalamic-pituitary-adrenal axis.
- insufficiency of, corticosteroid-induced, 528

Adrenocorticotropic hormone, in cortisol regulation, 559

Adverse drug reactions, corticosteroids for, 563

Aeroallergens. *See also* Pollen allergy.
- immunotherapy for, 426–428
- rhinoconjunctivitis due to, 266–268

Age, asthma and, 624–633

Agoraphobia, atopic disorders with, 410

Air pollution
- asthma induced by, 15–16
  - environmental tobacco smoke, 22–26
  - genetic factors in, 695–696
  - ozone, 16–20, 26
  - particulate matter, 20–22
- in hygiene hypothesis, 224–225, 275

Airway, hyperresponsiveness of. *See* Bronchial hyperresponsiveness.

Airway rewarming theory, of exercise-induced asthma, 32–33

Albuterol, for asthma
- exercise-induced, 36
- gastroesophageal reflux-induced, 134
- pharmacogenomics of, 727–731

Allergens
- as asthma triggers, **1–14**
  - *Alternaria*, 7–8
  - cockroach, 6–7
  - dust mite, 2–4
  - grass, 8–9

0889-8561/05/$ – see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/S0889-8561(05)00072-X

pet paradox and, 4–6
rodent, 6
fetal exposure to, 217

Allergic conjunctivitis, corticosteroids for, 567

Allergic contact dermatitis
corticosteroids for, 562
due to topical corticosteroids, 576–578

Allergic diseases, pediatric. *See* Pediatric patients, allergic diseases in.

Allergic eosinophilic gastroenteropathy, 375–377

Allergic fungal sinusitis, in pediatric patients, 316

Allergic march. *See* Atopic march.

Allergic rhinitis
corticosteroids for. *See* Corticosteroids, for allergic rhinitis.
in pediatric patients, **283–299**
attention deficit hyperactivity disorder with, 415
classification of, 283
cognitive effects of, **301–312**
comorbid disorders with, 284–285
depression with, 414
diagnosis of, 286
epidemiology of, 283–284
food allergy with, 372
immunotherapy for, 426, 434–436
pathophysiology of, 285
quality of life with, 284–285
rhinosinusitis in, 316
signs and symptoms of, 285–286
treatment of, 286–296, **301–312**
inflammation in, molecular basis of, 451–453

Allergic Rhinitis and its Impact on Asthma guidelines
corticosteroids in, 607–609
description of, 599–601

Allergy
food. *See* Food allergy.
gene–environment interactions in. *See* Environmental factors, in asthma.
to corticosteroids
systemic, 565–566
topical, 576–578

ALOX5 gene and product
as asthma trigger, 171–173
leukotriene inhibitors and, 732–733

Alternaria allergens, in asthma, 7–8

Amantadine, for respiratory infections, in asthma prevention, 59

Amcinonide, topical, potency of, 568

Amoxicillin, for rhinosinusitis, 324–326

Amoxicillin-clavulanate, for rhinosinusitis, 324–326, 329

Anaphylaxis, **389–405**
causes of, 391–394
corticosteroids for, 563
epidemiology of, 389–392
fatal, 389–394
food-dependent, exercise-induced, 154–155
grading of, 390–391
in food allergy, 150–151
in immunotherapy, 432–433
to drugs, 392–393
to latex, 395–401
to stinging insects, 393–394
treatment of, 394–395, 432–433

Angioedema, in pediatric patients, **353–367**
classification of, 356–358
differential diagnosis of, 359–360
epidemiology of, 354
evaluation of, 360–361
hereditary, 358–359
mechanisms of, 354–355, 358–359
pathogenesis of, 354–356
treatment of, 363

Angiotensin-converting enzyme inhibitors, asthma induced by, 183–185

Animal exposure
atopy protection from, 221–222, 253–254, 274
control of, 287
immunotherapy for, 428

Animal proteins, occupational asthma due to, 195–197

Annexin-1, corticosteroid effects on, 456

Antibiotics
for rhinosinusitis, 71–72, 324–326
in hygiene hypothesis, 255

Anticholinergic agents
for allergic rhinitis, 288, 291, 294
for asthma, pharmacogenomics of, 731
for exercise-induced asthma, 37

Antihistamines
for allergic rhinitis, 288–290, 292, 302–307, 608
for angioedema, 363
for atopic march prevention, 241–242
for urticaria, 361–363
sedating effects of, 302–307

Antioxidants, for food-induced asthma, 158–159

Antiprotease secretory leukoprotease inhibitor, corticosteroid effects on, 456

Anti-reflux surgery, for GERD, asthma outcome and, 138–139, 143

Antiviral agents, for respiratory infections, in asthma prevention, 59

Anxiety disorders, atopic disorders with, in pediatric patients, 407–412, 415–416

Aquagenic urticaria, 357

Arachidonic acid metabolites, as asthma triggers, 171–174

ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines
corticosteroids in, 607–609
description of, 599–601

Aspiration, in gastroesophageal reflux–triggered asthma, 136

Aspirin, asthma induced by, 169–180
clinical features of, 174–175
diagnosis of, 175–176
mechanisms of, 171–174
natural history of, 174–175
prevalence, 170–171
treatment of, 176–180

Asthma
adult-onset, phenotypes of, 625
age factors in, 624–633
angiotensin-converting enzyme inhibitor–induced, 183–185
aspirin-induced, 169–180
baker's, 159–160
beta-blocker–induced, 180–183
definition of, 598, 623
diagnosis of
exercise-induced, 34–35
occupational, 199–201
economic impact of, 641, 723
epidemiology of, 641, 723
exercise-induced, 31–32
food-allergy–induced, 149–150, 153–154
in infections, 46–50
exercise-induced, **31–43,** 154–155
fatal, in stress, 97–98
genetic factors in
ADAM33 gene in. *See* *ADAM33* gene.
age and, 624–633
candidate gene association studies, **681–708**
environmental interactions with, **709–721**
family studies in, **641–654**
gender and, 625–634
gene–gene interactions in, 696, 698–702, 744–748
HLA-G gene in, **669–679**
man–mouse homology mapping of, 748–751
new approaches to, **743–755**
penetrance in, 683
pharmacogenomics, **723–742**
phenotypes in. *See* Phenotypes, in asthma.
polygenetic nature of, 682–683, 696
in pediatric patients
allergic rhinoconjunctivitis with, 275
anxiety disorders with, 410–412, 416
atopic march in. *See* Atopic march.
depression with, 413–414
development of, hygiene hypothesis for. *See* Hygiene hypothesis.
immunotherapy for, 424–428, 434–436
ontogeny of, **215–229**
phenotypes of, 624–625
rhinosinusitis effects on, 328–329
inflammation in, molecular basis of, 451–453
intermittent, treatment of, 601
mild persistent, treatment of, 602–604, 706
moderate to severe, treatment of, 606, 608
moderate to severe persistent, treatment of, 604–606
mortality in, 641
outgrowing, 625
persistent, treatment of, 602
phenotypes in. *See* Phenotypes, in asthma.
progressive, *ADAM33* gene in, 663
reliever medications for, 598
severe, *ADAM33* gene in, 663
treatment of
aspirin-induced, 176–180
beta-blocker–induced, 182–183
controller medications for, 599
corticosteroids in. *See* Corticosteroids, for asthma.
exercise-induced, 37–41
in angiotensin-converting enzyme inhibitor therapy, 184–185
in GERD, 143–144
in respiratory infections, 60–61
nonadherence to, **107–130**
causes of, 108–129

economic burden of, 107–108
epidemiology of, 107
occupational, 202
pharmacogenomics of, **723–742**
tobacco-smoke–induced, 25–26
triggers of
allergens, **1–14**. *See also specific allergens.*
environmental, **15–30**
exercise, **31–43**, 154–155
food allergy, **149–167**
gastroesophageal reflux, **131–148**
infectious, **45–66**
medications, **169–190**
occupational exposures, 159–160, **191–205**
outdoor air pollution, **15–30**
patient nonadherence to treatment, **107–130**
rhinosinusitis, **67–82**
stress, **83–105**
undertreatment of, 534–535

Athletes, asthma in. *See* Exercise-induced asthma.

Atopic dermatitis. *See* Dermatitis, atopic.

Atopic keratoconjunctivitis, corticosteroids for, 562–563

Atopic march, **231–246**
cord blood immunoglobulin E in, 233
description of, 231–232
family history of, 232–233
genetic basis for, 237–238
in atopic dermatitis, 235–236
in wheezing, 236–237
mechanisms of, 237–238
prevention of, 237–243, 436
risk factors for, 232–237
sensitization in, 234–235

Atopy
definition of, 623
dermatitis in. *See* Dermatitis, atopic.
development of, hygiene hypothesis for. *See* Hygiene hypothesis.
in pediatric patients
in spina bifida, 398
psychiatric disorders with, **407–420**
ontogeny of, **215–229**

Atrophy, of skin, corticosteroid-induced, 575

Attention deficit hyperactivity disorder, atopic disorders with, 407–408, 414–416

Autoimmune urticaria, 355, 358, 360–361

Autonomic dysfunction, gastroesophageal reflux in, asthma in, 134

Avoidance
in allergic rhinitis, 286–288
in food allergy, 384
in latex allergy, 400–401
in occupational asthma, 202

Azelastine, for allergic rhinitis, 289–290

Azithromycin, for rhinosinusitis, 326

B

Bacille Calmette-Guerin vaccine, in hygiene hypothesis, 224

Bacterial culture, in rhinosinusitis, 323

Baker's asthma, 159–160

Beclomethasone
absorption of, 525
for allergic rhinitis, 290, 292
for asthma, pharmacogenomics of, 734–737
hypothalamic-pituitary-adrenal axis effects of, 544
inhaled
as prodrug, 475–476
bioavailability of, 526
chemical structure of, 471
clearance of, 477
devices for, 479, 545
for asthma, 511, 603
half-life of, 482
hypothalamic-pituitary-adrenal axis effects of, 549
in combination therapy, 605
oral bioavailability of, 476
pharmacokinetics of, 476–477, 479–482
potency of, 474
protein binding of, 480
pulmonary deposition in, 478
receptor affinity of, 474
volume of distribution of, 481
intranasal
for allergic rhinitis, 490
for otitis media, 501
for rhinosinusitis, 498
glaucoma due to, 503

Bee stings, anaphylaxis due to, 393–394

Beta-agonists, for asthma
occupational, 202
pharmacogenomics of, 727–731
with corticosteroids, 604–606

Beta-blockers
asthma induced by, 180–183
for exercise-induced asthma, 37
immunotherapy interactions with, 425

Betamethasone
inhaled, systemic effects of, 526
intranasal, systemic effects of, 526
systemic, for allergic rhinitis, 494
topical, potency of, 568–569

Bioavailability, oral, of inhaled corticosteroids, 470–471, 476

Bla allergens, in asthma, 7

Blomia tropicalis allergens, Der allergens, 2

Bone, corticosteroid effects on, 527–528, 535–536, 563–564

Bradykinin, angiotensin-converting enzyme inhibitors action on, 184

Brain, infections of, in rhinosinusitis, 328

Breastfeeding
atopic march and, 238–240
immune system development and, 220

Breathing, abnormal, asthma in, 75

Brompheniramine, for allergic rhinitis, 289

Bronchial hyperresponsiveness, in asthma
ADAM33 gene in, 656–658, 661
age considerations in, 628–629
gastroesophageal reflux–triggered, 135–136
gender considerations in, 629
HLA-G gene in, 673–674
in candidate gene analysis, 686

Bronchiolitis, respiratory syncytial virus, asthma in, 47, 49, 52–53

Bronchodilators, for asthma, in respiratory infections, 60

Budesonide
for allergic rhinitis, 290, 293
for exercise-induced asthma, 37, 40
for rhinosinusitis, 327
hypothalamic-pituitary-adrenal axis effects of, 544
inhaled
chemical structure of, 471
clearance of, 477
devices for, 479, 545
for asthma, 514–515, 517–518
for mild persistent asthma, 603
half-life of, 482
hypothalamic-pituitary-adrenal axis effects of, 548–549
in combination therapy, 605–606
oral bioavailability of, 476
pharmacokinetics of, 476–477, 479–483, 531
potency of, 474
protein binding of, 480
pulmonary deposition in, 478
pulmonary residence time of, 483
receptor affinity of, 474
systemic effects of, 526
volume of distribution of, 481–482
intranasal
adverse effects of, 503
for allergic rhinitis, 490
for rhinosinusitis, 497
glaucoma due to, 503
hypothalamic-pituitary-adrenal axis effects of, 549–550

Bullous dermatoses, corticosteroids for, 560

Byssinosis, occupational asthma due to, 195

C

C1 inhibitor
defects of, angioedema in, 358–359
replacement of, for angioedema, 363

Calcineurin inhibitors, for atopic dermatitis, 340–343

Candidate gene analysis, in asthma, **681–708**
ADAM33 gene. *See ADAM33* gene.
CARD genes, 692–695
CD14, 692–695
evidence for, 689–690
gene-by-gene interactions and, 696, 698–702
GSTT genes, 695–696
in pharmacogenomics, 726–727
interleukin signaling pathway, 697–702
list of, 685, 690
rationale for, 684–686
selection bias in, 687
selection of, 688–689
STAT genes, 697–698
study characteristics in, 686–687
Toll-like receptors, 692–695
unlimited supply of genes for, 687–688

CAP-RAST FEIA test, for food allergy, 162

Captopril, asthma induced by, 183–185

CARD genes
In asthma, 692–695
polymorphisms of, in hygiene hypothesis, 258

Caregiver stress, asthma and, 93–96

Caspase recruitment domain-containing protein 14, polymorphisms of, in hygiene hypothesis, 258

Cat allergy
asthma and, 4–6
immunotherapy for, 430–431

Cataract, corticosteroid-induced, 528

Cathelicidins, deficiency of, in atopic dermatitis, 336

CD14 gene
in asthma, endotoxin interactions with, 630, 692–695, 715–719
polymorphisms of, in hygiene hypothesis, 258

Celecoxib, asthma induced by, 177, 179

Celiac disease, food hypersensitivity in, 377, 379

Cephalosporins, for rhinosinusitis, 326

Ceramides, for atopic dermatitis, 338

Cetirizine
for allergic rhinitis, 289–290
for atopic march prevention, 241–242
for urticaria, 361–362

Challenge testing
in asthma
airborne particulate matter and, 21
aspirin-induced, 176
exercise-induced, 35–36
food-additive–induced, 157–158
occupational, 200
ozone-induced, 18–19
in food allergy, 379, 381–382

Chemicals, occupational asthma due to, 195–197

Chlamydia pneumoniae infections, asthma in, 47, 49, 54–55, 59–60

Chlorpheniramine
for allergic rhinitis, 289, 304
for urticaria, 361
sedating effects of, 304

Cholinergic urticaria, 356–357

CHRM genes, in asthma, anticholinergics and, 731

Chromatin, remodeling of, in inflammation, 452

Chronic obstructive pulmonary disease, corticosteroids for
adverse effects of, 527
resistance to, 464–465

Ciclesonide
inhaled
as prodrug, 475–476
chemical structure of, 471
clearance of, 477
for asthma, 511, 514
half-life of, 482
oral bioavailability of, 476
pharmacokinetics of, 476–478, 480, 482–483, 533
potency of, 474
protein binding of, 480
pulmonary deposition in, 478
pulmonary residence time of, 483
receptor affinity of, 474
intranasal, for allergic rhinitis, 490

Cilomulast, for exercise-induced asthma, 40

Cimetidine
for GERD, asthma outcome and, 139, 143
for urticaria, 362

Clarithromycin
for respiratory infections, in asthma prevention, 59–60
for rhinosinusitis, 326

Clobetasol, topical, potency of, 568

Cockroach allergens
asthma due to, 6–7
control of, 287
rhinoconjunctivitis due to, 272

Cognitive effects
of allergic rhinitis and treatment, **301–312**
future research on, 307–310
in sleep loss, 302
performance impairment, 301–307
sedation, 301–310
of corticosteroids, 565

Cold air, in inhalation challenge testing, in exercise-induced asthma, 36

Cold urticaria, 357

Colonization
intestinal, in hygiene hypothesis, 219–220, 254–255
skin, by *Staphylococcus aureus,* in atopic dermatitis, 335–336

Computed tomography, in rhinosinusitis, 68–69, 322

Conjunctivitis, allergic. *See* Rhinoconjunctivitis, allergic.

Connective tissue diseases, corticosteroids for, 560

Contact dermatitis, allergic
corticosteroids for, 562
due to topical corticosteroids, 576–578

Coronavirus infections, asthma in, 47–48, 50–51

Corticosteroids
adherence problems with, **581–595**

administration routes for, benefit versus risk and, 524–525, 531–534
adverse effects of, 503–504
fear of, 583–584, 591–593
in pediatric patients, 551
individual differences in, 535
inhaled, 473–474, 524–534
intranasal, 524–528, 534
molecular mechanisms of, 457–458
systemic, 563–566
topical, 524–525, 574–578
versus benefits, 523–539
benefit versus risk for, **523–539**
administration routes and, 524–525, 531–534
adverse effects in, 527–529
biologic effects in, 526–527
dosing and, 529–531
drug-related factors in, 524–534
individual factors in, 534–535
pharmacokinetics and pharmacodynamics of, 531–534
public health perspective of, 535–536
contraindications to
systemic, 561
topical, 573
dosage regimens for, **511–521**
for allergic inflammation, **489–509**
for allergic rhinitis, 288, 290–293
benefit versus risk of, 523–539
guidelines for, 599–601, 607–609
intranasal, 490–494
systemic, 494–495
for anaphylaxis, 432
for angioedema, 363
for asthma
aspirin-induced, 176–177
benefit versus risk of, 523–539
cellular effects of, 453–454
duration of, 515–516
exercise-induced, 37
guidelines for, Global Initiative for Asthma, 598–599, 601–606
inhaled. *See* Inhaled corticosteroids.
initiation of, 512–515
occupational, 202
pharmacogenomics of, 734–737
resistance to, 461–464
respiratory infections and, 60–61
step down in, 517–519
step up in, 516–517
tobacco-smoke–induced, 25–26
with allergic rhinitis, 492
with smoking, 464
for atopic dermatitis, 338–340, 343–344
for eye disorders, 562–563, 566–567
for otitis media, 499–502
for rhinosinusitis, 71–72, 326–327, 495–499
for skin disorders, **557–580**
for urticaria, 362–363
gastroesophageal reflux due to, asthma in, 134
hypothalamic-pituitary-adrenal axis effects of, **541–555**, 558–559
in gene transcription, 456–458
in inflammatory gene control, 458–461
in signal transduction, 461
indications for
systemic, 560–561
topical, 572
individual responses to, 534–535
inhaled. *See* Inhaled corticosteroids.
intranasal. *See* Intranasal corticosteroids.
mechanism of action of, 489–499
intranasal, 490–492
topical, 570
molecular mechanisms of, **451–468**
pharmacodynamics of, inhaled, 473–475
pharmacokinetics of
benefit versus risk and, 531–534
inhaled, 475–484, 531–534
intranasal, 534
oral, 531
pharmacology of, hypothalamic-pituitary-adrenal axis and, 542
phobia concerning, 571, 583–584, 591–593
potency of
topical, 568–569
vasoconstrictor assay for, 566
products for, inhaled, 471–472
receptors for.
See Glucocorticoid receptors.
resistance to, 461–465
safety of, 503–504
systemic. *See* Oral corticosteroids; Systemic corticosteroids.
topical. *See* Intranasal corticosteroids; Topical corticosteroids.
withdrawal from, 559, 561

Corticotropin, in cortisol regulation, 559

Corticotropin stimulation tests, for hypothalamic-pituitary-adrenal axis assessment, 543–544

Corticotropin-releasing hormone, in cortisol regulation, 559

Cortisol
measurement of, for hypothalamic-pituitary-adrenal axis assessment, 542–544
production and regulation of, 559

Cough
from angiotensin-converting enzyme inhibitors, 183–185
in exercise-induced asthma, 34

Cow's milk, hypersensitivity to, 377–379

Cramps, in exercise-induced asthma, 34

CRHR1 gene, in asthma, corticosteroids and, 736

Cromolyn
for allergic rhinitis, 291, 293
for exercise-induced asthma, 37

Cromones, for mild persistent asthma, 603

CTACK/CCL27 (cutaneous T-cell–attracting chemokine), in atopic dermatitis, 335

CTLA-4 gene, in asthma, 633–634

Culture, bacterial, in rhinosinusitis, 323

Cushingoid changes, corticosteroid-induced, 565

Cutaneous T-cell–attracting chemokine (CTACK/CCL27), in atopic dermatitis, 335

Cycle ergometer test, in exercise-induced asthma, 35–36

Cyclooxygenase, as asthma trigger, 171–173

Cyclosporine, for urticaria, 363

Cyproheptadine, for urticaria, 361–362

CYSLT1 gene, in asthma, leukotriene inhibitors and, 733–734

Cystic fibrosis, rhinosinusitis in, 318–319

Cytokines
corticosteroid effects on, 491–492
in asthma
ozone-induced, 18
rhinosinusitis and, 69–70, 75–76
stress and, 89–90, 95
in immune response, ontogeny of, 215, 218–219
in respiratory infections, asthma and, 56
in stress, 86–87, 89–90, 95

Cytotoxic T lymphocyte-associated 4 receptor, in asthma, 633–634

D

Danazol, for angioedema, 363

Darier's sign, in mastocytoma, 359

Daycare, hygiene hypothesis and, 248–249

Decongestants
for allergic rhinitis, 288, 292
for rhinosinusitis, 327

Defensins, deficiency of, in atopic dermatitis, 336

Delayed-pressure urticaria, 357

Depression
asthma in, 96–97
in pediatric patients, atopic disorders with, 407–408, 412–416

Der allergens, in asthma, 2–4

Dermatitis
allergic contact
corticosteroids for, 562
to topical corticosteroids, 576–578
atopic
corticosteroids for, 562, 573
in pediatric patients, **333–351**
anxiety disorders with, 411
atopic march in. *See* Atopic march.
impact of, 333–334
in food allergy, 375
pathophysiology of, 334–337
treatment of, 337–345
corticosteroids for, 560, 562, 572–573
perioral, corticosteroid-induced, 575
stasis, corticosteroids for, 573

Dermatoconjunctivitis, allergic, corticosteroids for, 562

Dermatology Life Quality Index, in urticaria, 361

Dermatophagoides allergens, in asthma, 2–4

Desensitization, to aspirin, for asthma, 179–180

Desloratadine
for allergic rhinitis, 289
for urticaria, 361

Desoximetasone, topical, potency of, 568

Dexamethasone
inhaled
potency of, 474
receptor affinity of, 474
intranasal, for rhinosinusitis, 497, 499

Diabetes mellitus, corticosteroids and, 564

Diaphragm, dysfunction of, gastroesophageal reflux in, asthma in, 134

Diary, diet, in food allergy, 379–380

Diesel exhaust, asthma induced by, 21–22

Diet
elimination, for food allergy, 380, 383
for exercise-induced asthma, 40

Diet diary, in food allergy, 379–380

Dietary protein enterocolitis, 377–379

Diflorasone diacetate, topical, potency of, 568

Diphenhydramine
for allergic rhinitis, 289, 303–306
for anaphylaxis, 432
for angioedema, 363
for urticaria, 361
sedating effects of, 303–306

DNA analysis, on candidate genes, in pharmacogenomics, 725–726

Dog allergens, asthma and, 4–6

Doping considerations, in exercise-induced asthma treatment, 40–41

Doxepin, for urticaria, 361

DPP10 gene, in asthma, 650–651, 750

Driving performance, antihistamine effects on, 309

Drugs
anaphylaxis due to, 392–393
asthma induced by, **169–190**
angiotensin-converting enzyme inhibitors, 183–185
aspirin, 169–180
beta-blockers, 180–183
nonsteroidal anti-inflammatory drugs, 169–180
pharmacogenomics of, **723–742**

Dry powder inhalers, for corticosteroids, 479, 512, 544–545

Dust mite allergy
immunotherapy for, 430
in asthma, 2–4
mite control for, 243, 287

Dyes, food, asthma induced by, 157

Dyshidrotic eczema, topical corticosteroids for, 573

Dysthymic disorder, atopic disorders with, 412–414

E

Ebastine, for urticaria, 361–362

Eczema, corticosteroids for, 573

Egg allergy
anaphylaxis in, 151
sensitization in, 234–235

Elimination diet, in food allergy, 380, 383

Enalapril, asthma induced by, 183–185

Endoscopy, in GERD, 141–142

Endotoxin
atopy protection from, 221, 253
in asthma, 5
CD14 interactions with, 630, 693–695, 715–719

Enoxaparin, for exercise-induced asthma, 40

Enterocolitis, dietary protein, 377–379

Environmental control, for allergic rhinitis, 286–288

Environmental factors, in asthma
ADAM33 gene and, 663–664
air pollution, 15–22
candidate gene analysis and, 681–682
environmental tobacco smoke, 22–26
gene interactions with, **709–721**
biology of, 718–719
concept of, 709–713
endotoxin-CD14, 630, 693–695, 715–716
marginal effects and, 713–715
nonlinear effects in, 717–718
occupational. *See* Occupational asthma.

Environmental pollutants, in hygiene hypothesis, 224–225, 275

Enzymes, occupational asthma due to, 159, 197

Eosinophils
corticosteroid effects on, 491
in asthma, rhinosinusitis and, 75–77

Eotaxin, in asthma, rhinosinusitis and, 75–76

Ephedrine, for allergic rhinitis, 292

Epinephrine
for anaphylaxis, 394–395, 432–433
for food allergy, 385

Epistasis, in interleukin signaling pathway, 701–702

Epithelial cells, ozone damage of, 18

Ergometer test, in exercise-induced asthma, 35–36

Erythema multiforme
corticosteroids for, 563
versus urticaria, 359

Esomeprazole, for GERD, asthma outcome and, 142

Esophagitis, in gastroesophageal reflux. *See* Gastroesophageal reflux.

Esophagography, in GERD, 142

Esophagus, reflux into. *See* Gastroesophageal reflux.

Eucapnic voluntary hyperventilation test, in exercise-induced asthma, 36

Euroglyphus maynei allergens, in asthma, 2

Exercise-induced asthma, **31–43**
- challenge testing in, 35–36
- diagnosis of, 34–35
- doping considerations in, 40–41
- epidemiology of, 31–32
- food-dependent, 154–155
- future therapies for, 40
- pathophysiology of, 32–34
- treatment of, 37–41

Eye disorders, corticosteroids for, 562–563, 566–567

F

Family
- history of allergic disease in, 233, 270–271
- size of, in hygiene hypothesis, 248–249
- stress in, asthma and, 93–96

Family studies, of asthma, **641–654**
- chromosome 1p, 645–646
- chromosome 2q, 646
- chromosome 5q, 646–647
- chromosome 6p, 647
- chromosome 12q, 647
- determination of genetic component in, 642
- genome-wide screening in, 642–645
- positional cloning in, 648–651

Famotidine, for GERD, asthma outcome and, 142

Farm environment, in hygiene hypothesis, 221, 252

Fatigue, in exercise-induced asthma, 34

Fel allergens, asthma and, 5–6

Fetus
- *ADAM33* gene expression in, 663–664
- immune system development in, 216–218

Fexofenadine
- for allergic rhinitis, 289–290, 303
- for urticaria, 361–362
- sedating effects of, 303

Fibroblasts, *ADAM33* gene expression in, 659–663

Filariasis, prenatal allergic sensitization to, 217–218

Fingertip Unit, for topical corticosteroid application, 571

Fire ant stings, anaphylaxis due to, 393–394

Fish allergy, asthma in, 159

Fish oil supplements, for asthma
- exercise-induced, 40
- food-induced, 158–159

FKBP proteins, in asthma, 734

FLAP (5-lipoxygenase activating protein)
- as asthma trigger, 171–173
- leukotriene inhibitors and, 733

Flour, occupational asthma due to, 159–160

Fluid therapy, for anaphylaxis, 395

Flunisolide
- for allergic rhinitis, 291–292
- for exercise-induced asthma, 37
- inhaled
  - chemical structure of, 471
  - half-life of, 482
  - hypothalamic-pituitary-adrenal axis effects of, 544, 547–548
  - oral bioavailability of, 476
  - pharmacokinetics of, 476, 480
  - protein binding of, 480
  - pulmonary deposition in, 478
- intranasal
  - for allergic rhinitis, 490
  - hypothalamic-pituitary-adrenal axis effects of, 549–550

Fluocinolone, topical, potency of, 568

Fluocinonide, topical, potency of, 568

Flurandrenolide, topical, potency of, 568

Fluticasone
- for allergic rhinitis, 290–291, 307
- for exercise-induced asthma, 37–38
- inhaled
  - absorption of, 525
  - chemical structure of, 471
  - clearance of, 477
  - devices for, 545–546
  - for asthma, 511, 514
  - half-life of, 482
  - hypothalamic-pituitary-adrenal axis effects of, 544, 546–549
  - in combination therapy, 605, 608

oral bioavailability of, 476
pharmacokinetics of, 476–478, 480–482, 531–533
potency of, 474
protein binding of, 480
pulmonary deposition in, 478
receptor affinity of, 474
systemic effects of, 526
volume of distribution of, 481–482
intranasal
absorption of, 525
for allergic rhinitis, 490, 493
for rhinosinusitis, 497
glaucoma due to, 503
hypothalamic-pituitary-adrenal axis effects of, 549–550
topical, potency of, 568

Focus groups, for asthma treatment adherence study, **107–130**

Food additives, asthma induced by, 155–158

Food allergy, **149–167**
additive-induced, 155–158
anaphylaxis in, 150–151, 154–155
asthma in
epidemiology of, 149–150, 153–154
from particle inhalation, 161
occupational, 159–161
severe, 150
skin testing for, 161–162
food-dependent, exercise-induced
anaphylaxis in, 154–155
in pediatric patients, **369–388**.
atopic march in. *See* Atopic march.
attention deficit hyperactivity disorder with, 415
clinical manifestations of, 372–382
diagnosis of, 379–384
epidemiology of, 369–370
immunoglobulin E-mediated, 371–375
latex allergy with, 400
non–immunoglobulin E-mediated, 372, 375–379
pathophysiology of, 371–382
patient education on, 385–386
pollen-associated, 372–374
prognosis for, 386
reaction types in, 369–370
rhinitis in, 270–271
terminology of, 369–371
treatment of, 384–386
omega-3-fatty acids protection in, 158–159
oral allergy syndrome in, 151–153
rhinitis in, 151

Food challenge tests, in food allergy, 379, 381–382, 384

Food hypersensitivity
clinical manifestations of, 372–379
definition of, 370

Food intolerance, definition of, 370–371

Forced expiratory volume in one second, in exercise-induced asthma, 200

Foreign body obstruction, rhinosinusitis in, 317

Formoterol, for asthma
exercise-induced, 37, 40
pharmacogenomics of, 727–731
with corticosteroids, 604–606

Formulas, infant, for atopic march prevention, 240–241

Functional endoscopic sinus surgery, for rhinosinusitis, asthma improvement and, 72–73

Fundoplication, for GERD, asthma outcome and, 143

Fungal sinusitis, allergic, in pediatric patients, 316

G

Gaining Optimal Asthma Control (GOAL) study, 605

Gastroenteropathy, allergic eosinophilic, 375–377

Gastroesophageal reflux disease
asthma in, **131–148**
asthma treatment in, 143–144
epidemiology of, 131–133
mechanisms of, 135–136
predisposing factors to, 133–134
reflux diagnosis in, 140–142
reflux treatment in, 142–143
reflux treatment outcomes and, 136–139
response predictors in, 139–140
silent, 132
rhinosinusitis in, 318

Gastroplasty, endoscopy, for GERD, asthma outcome and, 143

Gender, in asthma, phenotypes of, 625–634

Gene–gene interactions, in asthma, 696, 698–702, 744–748

Generalized anxiety disorder, atopic disorders with, 409–411

Genetic association analysis, in asthma, in pharmacogenomics, 726–727

Genetic factors
in allergic disease, 215–216, 412
in asthma. *See* Asthma, genetic factors in.
in atopic march, 237–238
in hygiene hypothesis, 258–259

Genome scans, in asthma, 642–645, 750

Genotypes, environment interactions with, 710–713

GERD. *See* Gastroesophageal reflux disease.

GINA (Global Initiative for Asthma) guidelines
corticosteroids in, 601–606
description of, 598–599

Glaucoma, corticosteroid-induced, 503, 528, 577–578

Global Initiative for Asthma guidelines
corticosteroids in, 601–606
description of, 598–599

Glucagon, for anaphylaxis, 395, 432

Glucocorticoid receptors, 454–456, 463
drug potency and, 474–475
in asthma, pharmacogenomics of, 734–737
in gene transcription, 458–459
in steroid-resistant asthma, 463
inhaled corticosteroid interactions with, 473–475

Glucocorticoid-induced leucine zipper protein, corticosteroid effects on, 456–457

Glucocorticosteroids. *See* Corticosteroids.

Glutathione S-transferase polymorphisms, asthma and, 20, 630–631, 695–696

GOAL (Gaining Optimal Asthma Control) study, 605

GPRA gene, in asthma, 649–650

Granulocyte-macrophage colony-stimulating factor, in asthma
ozone-induced, 18
rhinosinusitis and, 75–77

Grass allergens, in asthma, 8–9

Grass pollen, rhinoconjunctivitis due to, 266–268

Growth restriction, corticosteroid-induced, 503–504, 528

GSTT genes, in asthma, 630–631, 695–696

H

Haemophilus influenzae, in rhinosinusitis, 319, 325–326

Halcinonide, topical, potency of, 568

Halobetasol, topical, potency of, 568

Haplotype analysis, in pharmacogenomics, 726–726

Hay fever, development of, hygiene hypothesis for. *See* Hygiene hypothesis.

Heat shock proteins, in asthma, 734

Helicobacter pylori infections, in hygiene hypothesis, 223

Helminthic infections, prenatal allergic sensitization to, 217–218

Hepatitis A, in hygiene hypothesis, 223, 250–252

Hereditary angioedema, 358–359

Herpes simplex virus infections, in hygiene hypothesis, 223, 251

Hev antigens, in latex allergy, 399–400

Hiatal hernia, gastroesophageal reflux in, asthma in, 134

Histamine
in food allergy, 271
in inhalation challenge testing, in exercise-induced asthma, 36

Histamine$_2$ receptor antagonists, for GERD, asthma outcome and, 137, 142–143

Histone
acetylation of
corticosteroid effects on, 459
defects in, in steroid-resistant asthma, 463–464
in inflammation, 453
deacetylation of, in inflammation, 453
methylation of, 459–460
phosphorylation of, 459–460
ubiquitination of, 459–460

Histone acetyltransferases and coactivators, in inflammation, 452

Histone deacetylases and corepressors
corticosteroid effects on, 459
in inflammation, 453

Histone methytransferases, corticosteroid effects on, 460

Hit and Run Hypothesis, of asthma, 45

Hives. *See* Urticaria.

HLA-G gene, in asthma, **669–679**
early studies of, 669
expression in lung, 675–676

founder population of, 672–674
genotyping of, 671–672
in pregnancy, 674–675
polymorphisms of, 676
positional cloning on chromosome 6p, 670–671
structure of, 671–672, 676
unusual nature of, 676
ying-yang haplotypes and, 672–674

Homology mapping, man–mouse, in asthma, 748–751

Honeybee stings, anaphylaxis due to, 393–394

Hornet stings, anaphylaxis due to, 393–394

House dust mite allergy
immunotherapy for, 430
in asthma, 2–4
mite control for, 243, 287

Human metapneumovirus infections, asthma in, 47, 49, 53–54

Hydration, skin, for atopic dermatitis, 337–338

Hydrocortisone
for anaphylaxis, 432
topical, potency of, 568

Hydrofluoroalkane propellants, for inhaled corticosteroids, pharmacokinetics and, 479

Hydroxyzine
for allergic rhinitis, 289
for urticaria, 361–362

Hygiene hypothesis, 220–236, **247–262**
allergic rhinoconjunctivitis and, 273–275
antibiotics and, 255
asthma and, 45
bowel flora and, 219–220, 254–255
clinical implications of, 259–260
contact with other children and, 248–249
endotoxin exposure and, 221, 253
farm environment and, 221, 252
genetic factors in, 258–259
mechanisms of, 256–258
overview of, 247
pet exposure and, 221–222, 253–254, 274
protective effect of infections, 222–223, 249–252, 254–255
vaccinations and, 223–224, 255

Hymenoptera venom, anaphylaxis due to, 393–394

Hyperglycemia, corticosteroid-induced, 564

Hyperosmolarity theory, of exercise-induced asthma, 32–33

Hypersensitivity, food
clinical manifestations of, 372–379
definition of, 370

Hypertension, corticosteroid-induced, 564–565

Hypertrichosis, corticosteroid-induced, 575–576

Hypothalamic-pituitary-adrenal axis
components of, 558
corticosteroid effects on, **541–555**
assessment of, 542–544
clinical significance of, 551–552
in pediatric patients, 551
inhaled, 544–549
pharmacology of, 542
topical, 549–551
dysregulation of, atopy and, 416
physiology of, 557–559
regulatory mechanisms of, 558
steroid withdrawal syndrome and, 559, 561

I

Immune response, to respiratory infections, 55–56

Immune system
development of, hygiene hypothesis for. *See* Hygiene hypothesis.
in atopic dermatitis, 334–335
stress effects on, 89–90

Immune-mediated urticaria, 354–355

Immunodeficiency
immunotherapy in, 425
rhinosinusitis in, 318

Immunoglobulin A deficiency, rhinosinusitis in, 318

Immunoglobulin E
fetal production of, 217–218
in anaphylaxis, 390
in asthma
age and gender considerations in, 626–627, 631
dust mites and, 3
occupational, 193–194, 200
rhinosinusitis and, 77
in cord blood, as atopy predictor, 233
in food allergy, 371–375

Immunophilins, in asthma, 734

Immunotherapy, for pediatric allergic diseases, **421–439**
aeroallergens, 426–428
allergic rhinitis, 294
atopic march, 242, 436
contraindications to, 424–426
discontinuation of, 433–434
dosing schedules for, 429–433
efficacy of, 426–429
emergency equipment for, 432–433
food allergy, 385
immunostimulatory molecules for, 435–436
in pregnancy, 425
insect venom reactions, 428–429
novel immunomodifiers for, 434–435
patient selection for, 422–426
rush schedule for, 431–432
sublingual, 435

Improving Asthma Control Trial (IMPACT), 603–604

Indoor allergens, 268

Infections
asthma in, **45–66**
adenovirus, 47–48, 51–52
Chlamydia pneumoniae, 47, 49, 54–55, 59–60
coronavirus, 47–48, 50–51
epidemiology of, 46–50
immunopathology of, 55–56
influenza virus, 47–48, 51, 58–59
interactions in, 56–57
metapneumovirus, 47, 49, 53–54
Mycoplasma pneumoniae, 47, 49, 54–55, 59–60
parainfluenza virus, 47–48, 53
respiratory syncytial virus, 47, 49, 52–53
rhinovirus, 47–48, 50
treatment of, 57–61
wheezing phenotypes in, 55
in hygiene hypothesis, 222–223, 249–252, 254–255
in stress, 87

Inflammation
cellular aspects of, 453–454
gene transcription and, corticosteroid effects on, 456–461
in asthma
exercise-induced, 33
gastroesophageal reflux–triggered, 136
ozone-induced, 17–18
rhinosinusitis and, 69–70, 75–76
tobacco-smoke–induced, 23–24
molecular basis of, 451–453
pathophysiology of, 469–471
signal transduction in, corticosteroid effects on, 461
steroid resistance in, 461–465

Influenza, asthma in, 47–48, 51, 58–59

Inhaled corticosteroids, **469–488**
absorption of, 525, 531–533
adherence to, barriers to, 584–596
as controller agents, 599
benefit versus risk of, 524–534
devices for. *See* Inhalers, for corticosteroids.
doses for, 529–531
fate of, 473
for mild persistent asthma, 602
hypothalamic-pituitary-adrenal axis effects of, 544–549
in combination therapy, 604–606
indications for, 469–471
liposomal formulations of, 484
pharmacodynamics of, 473–475, 546–548
pharmacokinetics of, 475–484
benefit versus risk ratio and, 531–534
clearance, 477
half-life, 482
hypothalamic-pituitary-adrenal axis and, 546–548
lung deposition, 477–479
oral bioavailability, 470–471, 476
particle size, 480
prodrug design and, 475–476
protein binding, 480–481
pulmonary residence time, 483–484
versus device type, 479–480
volume of distribution, 481–482
products for, 471–472
receptor potency and, 474–475
systemic effects of, 527–529
therapy with, **511–521**
duration of, 515–516
initiation of, 512–515
step down in, 517–519
step up in, 516–517

Inhalers, for corticosteroids, 512
drug fate and, 473
hypothalamic-pituitary-adrenal axis and, 544–546
pharmacokinetics and, 479–480
types of, 479–480

Insecticides, organophosphate, asthma due to, 195

Insects, stinging
anaphylaxis due to, 393–394
immunotherapy for, 423, 428–429

Insertion/deletion polymorphisms, in asthma, 724

Insulin tolerance test, for hypothalamic-pituitary-adrenal axis assessment, 544

Interferon(s), in asthma, respiratory infections and, 56

Interferon-γ
corticosteroid effects on, 491–492
in asthma
rhinosinusitis and, 69
stress and, 89–90
in immune response, ontogeny of, 215, 218–219

Interleukin(s)
corticosteroid effects on, 456, 458, 491–492
in asthma, 470
ozone-induced, 18
respiratory infections and, 56
rhinosinusitis and, 69–70, 75–77
signaling pathway genes polymorphisms in, 631, 697–702
tobacco-smoke–induced, 23–24
in immune response, ontogeny of, 215, 218–219

Interleukin-1β, gene for, in asthma, 634

Interviews, for asthma treatment adherence study, **107–130**

Intestinal flora, in hygiene hypothesis, 219–220, 254–255

Intolerance, food, definition of, 370–371

Intranasal corticosteroids
administration routes for, 492
adverse effects of, 503–504
benefit versus risk of, 524–528, 534
for allergic rhinitis, 490–494, 608
for otitis media, 499–502
for rhinosinusitis, 495–499
hypothalamic-pituitary-adrenal axis effects of, 549–551
pharmacokinetics of, 534
safety of, 503–504
systemic effects of, 527–529

Ipratropium bromide
for allergic rhinitis, 291, 294
for asthma
exercise-induced, 37
pharmacogenomics of, 731

Irritants, in occupational asthma, 195

Isoproterenol, for asthma, pharmacogenomics of, 728

K

Kartagener's syndrome, rhinosinusitis in, 319

Keratoconjunctivitis, atopic, corticosteroids for, 562–563

Ketotifen
for atopic march prevention, 242
for urticaria, 362

Knemometry, bone evaluation, in corticosteroid therapy, 527

L

Lactobacillus
for allergy prevention, 219–220, 241
for atopic dermatitis, 344–345

Langerhans cells, corticosteroid effects on, 491

Lansoprazole, for GERD, asthma outcome and, 142–143

Latex allergy, in pediatric patients, 395–401
allergens in, 396–397, 399–400
food reactions and, 400
in spina bifida, 397–401
prevention of, 400–401
risk for, 397–399

Leukotriene(s), as asthma triggers, 171–174

Leukotriene antagonists
for allergic rhinitis, 288, 291, 293–294
for asthma
aspirin-induced, 177
in respiratory infections, 61
pharmacogenomics of, 732–734
for urticaria, 362

Leukotriene synthase, as asthma trigger, 171–173

Levocetirizine
for allergic rhinitis, 303
for urticaria, 361–362

Lichen simplex chronicus, topical corticosteroids for, 573

Lifestyle changes
for atopic dermatitis, 337
for exercise-induced asthma, 36
for GERD, asthma outcome and, 142

Linkage analysis, in asthma, 643–647, 669, 684–685

Lipocortin-1, corticosteroid effects on, 456

Liposomal formulations, of corticosteroids, 484

5-Lipoxygenase, as asthma trigger, 171–173

5-Lipoxygenase activating protein
as asthma trigger, 171–173
leukotriene inhibitors and, 733

Lisinopril, asthma induced by, 183–185

Local axonal reflex, in gastroesophageal reflux–triggered asthma, 135

Log of odds score, in family studies, of asthma, 643

Loratadine
for allergic rhinitis, 289–290, 306–307
for urticaria, 361–362
sedating effects of, 306–307

Lung
ADAM33 gene expression in, 663–665
HLA-G gene expression in, 675–676
inhaled corticosteroid deposition in, 477–479
inhaled corticosteroid residence time in, 483–484

M

Magnetic resonance imaging, in rhinosinusitis, 69, 323

Man–mouse homology mapping, in asthma, 748–751

Mannitol, in inhalation challenge testing, in exercise-induced asthma, 36

Mast cell(s)
corticosteroid effects on, 491
in food allergy, 271

Mast-cell stabilizers, for allergic rhinitis, 288, 291, 293

Mastocytoma, versus urticaria, 359

Measles, in hygiene hypothesis, 223–224, 249–251

Mesenchymal cells, *ADAM33* gene expression in, 663

Metapneumovirus infections, asthma in, 47, 49, 53–54

Metaproterenol, for exercise-induced asthma, 37

Metered-dose inhalers, for corticosteroids, 479, 512, 545–546

Methylprednisolone, for anaphylaxis, 432

Metoclopramide, for GERD, asthma outcome and, 143

Metyrapone test, for hypothalamic-pituitary-adrenal axis assessment, 544

Microarray technology, in candidate gene analysis, in asthma, 686

Microaspiration, in gastroesophageal reflux–triggered asthma, 136

Microflora, intestinal, in hygiene hypothesis, 219–220, 254–255

Milk allergy, anaphylaxis in, 151

Minute ventilation, increased, in gastroesophageal reflux–triggered asthma, 136

Mite allergy
immunotherapy for, 430
in asthma, 2–4
mite control for, 243, 287

Mitogen-activated protein kinase(s)
corticosteroid effects on, 461
in steroid-resistant asthma, 463

Mitogen-activated protein kinase phosphatase-1, corticosteroid effects on, 456–457

Mizolastine, for urticaria, 362

Moisturizers, for atopic dermatitis, 337–338

Mold, control of, 287–288

Mometasone furoate
for allergic rhinitis, 290–291, 293
for rhinosinusitis, 327
inhaled
chemical structure of, 471
for asthma, 511, 514
half-life of, 482
hypothalamic-pituitary-adrenal axis effects of, 546–548
oral bioavailability of, 476
pharmacokinetics of, 476, 478, 480, 482
potency of, 474
protein binding of, 480
receptor affinity of, 474
intranasal
for allergic rhinitis, 490
glaucoma due to, 503
hypothalamic-pituitary-adrenal axis effects of, 549–550
topical, potency of, 568

Monosodium glutamate, asthma induced by, 157

Montelukast
for allergic rhinitis, 291, 293–294
for asthma
exercise-induced, 37
in combination therapy, 606, 608
mild persistent, 603
for urticaria, 362
pharmacogenomics of, 732–734

Moraxella catarrhalis, in rhinosinusitis, 319, 325–326

Mouse allergens
asthma due to, 6
rhinoconjunctivitis due to, 272

Mouth, dermatitis near, corticosteroid-induced, 575

Mycoplasma pneumoniae infections, asthma in, 47, 49, 54–55, 59–60

N

Nasal polyps
corticosteroids for, 495–499
rhinosinusitis in, 317–318

Naso-pharyngo-bronchial reflexes, in asthma, 73–74

Natural rubber latex allergy, 395–401

Nebulizers, for corticosteroids, 479, 545

Nedocromil, for asthma, 37, 603

Neonates, immune system development in, 218–220

Neurogenic inflammation, in gastroesophageal reflux–triggered asthma, 136

Neurokinin, angiotensin-converting enzyme inhibitors action on, 184

Nicotinamide adenine dinucleotide phosphate–reduced quinone oxidoreductase polymorphisms of, asthma and, 20

Nitric oxide, in asthma
dust mites and, 3–4
exercise-induced, 33

Nizatidine, for GERD, asthma outcome and, 142

NOD (CARD) genes, In asthma, 692–695

Nonallergic rhinoconjunctivitis, in pediatric patients
differential diagnosis of, 268–270
with eosinophils, 269

Nonsteroidal anti-inflammatory drugs, asthma induced by, 169–180
clinical features of, 174–175
diagnosis of, 175–176
mechanisms of, 171–174
natural history of, 174–175
prevalence, 170–171
treatment of, 176–180

Norm of reaction, in gene–environment interactions, 710

Nose
corticosteroid administration to. *See* Intranasal corticosteroids.
polyps of
corticosteroids for, 495–499
rhinosinusitis in, 317–318

NR3C1 gene, in asthma, corticosteroids and, 734–735

Nuclear factor-κB
glucocorticoid receptor interaction with, 459, 463
in inflammation, 453
in ozone-induced asthma, 18
inhibitors of, 456

Nut allergy, anaphylaxis in, 151

O

Obsessive-compulsive disorder, atopic disorders with, 410

Occupational asthma, **191–205**
agents causing, 195–197
diagnosis of, 199–201
differential diagnosis of, 201
economic burden of, 192
food-related, 159–160
historical view of, 191
history taking in, 198
irritant mechanisms of, 195
molecular weight of agents and, 193–197
pathophysiology of, 193–195
pharmaco-physiologic actions in, 196
physical examination in, 198–199
prevalence of, 192–193
prognosis for, 202–203
symptomatology of, 197–198
treatment of, 202
with latency, 193–194

Omalizumab
for allergic rhinitis, 294, 296, 434
for asthma, 434, 608

Omeprazole, for GERD
asthma outcome and, 137–138, 142–144
diagnostic use of, 141

One airway hypothesis, of asthma and rhinosinusitis, 76–77

Ontogeny, of allergic inflammatory responses, **215–229**
breastfeeding, 220
early childhood, 220–225
family history and, 216

genetic studies of, 215–216
intrauterine environment, 216–218
neonatal period, 218–220

Oral allergy syndrome, 151–153, 372–374

Oral corticosteroids
benefit versus risk of, 524–527, 530–531
pharmacodynamics of, 531
pharmacokinetics of, 531

Orbit, infections of, in rhinosinusitis, 328

Organophosphates, asthma due to, 195

Oseltamivir, for respiratory infections, in asthma prevention, 59

Osteomeatal complex, obstruction of, rhinosinusitis in, 314–315

Osteonecrosis, corticosteroid-induced, 564

Osteoporosis, corticosteroid-induced, 535–536, 563–564

Otitis media, corticosteroids for, 499–502

Oxandrolone, for angioedema, 363

Oxymetazoline, for allergic rhinitis, 292

Ozone, asthma induced by, 16–20, 26

P

p38 mitogen-activated protein kinase, in steroid-resistant asthma, 463

Pain, abdominal, in exercise-induced asthma, 34

Panic attacks, atopic disorders with, 410–412

Pankukast, for asthma, mild persistent, 603

Pantoprazole, for GERD, asthma outcome and, 142

Parainfluenza virus infections, asthma in, 47–48, 53

Paranasal sinusitis. *See* Rhinosinusitis.

Parasitic infections
in hygiene hypothesis, 254–255
prenatal allergic sensitization to, 217–218

Particle size, of inhaled corticosteroids, 480

Particulate matter, airborne, asthma induced by, 20–22

Peanut allergy, anaphylaxis in, 151

Pediatric patients
allergic diseases in
anaphylaxis, **389–405,** 432–433
angioedema, **353–367**
asthma. *See* Asthma, in pediatric patients.
atopic dermatitis, **333–351,** 411
atopic march in, **231–246,** 436
food, **369–388,** 400, 415
hygiene hypothesis of. *See* Hygiene hypothesis.
immunotherapy for, 242, 294, 385, **421–439**
ontogeny of, **215–229**
psychiatric comorbidity with, **407–420**
rhinitis. *See* Allergic rhinitis, in pediatric patients.
rhinoconjunctivitis, **263–281**
rhinosinusitis, **313–332**
urticaria, **353–367**
asthma in
environmental tobacco smoke and, 22–25
nonadherence with treatment and, 125–126
phenotypes of, 624–625
rhinosinusitis and, **67–82**
with GERD, 143
corticosteroids for
adherence issues in, 585–586
adverse effects of, 551
hypothalamic-pituitary-adrenal axis effects of, 551
inhaled, 544–549

Penetrance, of asthma genes, 683

Penicillin
anaphylaxis due to, 392
for rhinosinusitis, 324

Peptic ulcer disease, corticosteroid-induced, 565

Performance impairment, in allergic rhinitis and treatment, 301–307

Perioral dermatitis, corticosteroid-induced, 575

Pertussis, in hygiene hypothesis, 250

Pet exposure
asthma and, 4–6
atopy protection from, 221–222, 253–254, 274
immunotherapy for, 428

pH testing, esophageal, in GERD, 141

Pharmacogenomics, of asthma, **723–742**
anticholinergics, 731
beta agonists, 727–731
corticosteroids, 734–737,

definition of, 724
genetic polymorphisms and, 724–727
leukotriene inhibitors, 732–734

Pharyngo-bronchial reflexes, in asthma, 73–74

Phenotypes, in asthma, **621–639**
contradicting data on, 621–622
definition of, 621–624
environment interactions with, 710–713
in candidate gene analysis, 688–689
in genome-wide association studies, 752
in pediatric patients, 624–625

Phenylephrine, for allergic rhinitis, 292

PHF11 gene, in asthma, 649, 750

Phobias, atopic disorders with, 409–410

Physical urticaria, 356–357

Pimecrolimus, for atopic dermatitis, 340–342

Pituitary gland. *See* Hypothalamic-pituitary-adrenal axis.

Plicatic acid, occupational asthma due to, 194

Pneumococcal infections, rhinosinusitis, 319, 324–325

Pollen allergy
asthma in, ozone interactions with, 19
environmental controls in, 288
food allergy associated with, 372–374
immunotherapy for, 426–427, 429, 431, 436
rhinoconjunctivitis in, 266–268

Pollen food allergy (oral allergy syndrome), 151–153

Pollutants, environmental, in hygiene hypothesis, 224–225, 275

Pollution, air. *See* Air pollution.

Polyaromatic hydrocarbons, in diesel exhaust, asthma induced by, 21–22

Polymorphisms
databases for, 725
in asthma, 724–726. *See also specific genes.*
single nucleotide. *See* Single nucleotide polymorphisms.

Polyps, nasal
corticosteroids for, 495–499
rhinosinusitis in, 317–318

Polysaccharides, occupational asthma due to, 195–196

Positional cloning, in family studies, of asthma, 648–651

Postnasal drip, asthma in, 74–75

Post-traumatic stress disorder, atopic disorders with, 410–411

Prednicarbate, topical, potency of, 568

Prednisolone
absorption of, 525
for allergic rhinitis, 494
for otitis media, 500–502

Prednisone
for allergic contact dermatitis, 562
for anaphylaxis, 432
for asthma, pharmacogenomics of, 734–737
for atopic dermatitis, 562
for otitis media, 500–501
for uveitis, 563
gastroesophageal reflux due to, asthma in, 134
hyperglycemia due to, 564
osteoporosis due to, 564

Pregnancy
fetal immune system development in, 216–218
HLA-G gene in, 674–675
smoking in, childhood asthma and, 25

Primary ciliary disease, rhinosinusitis in, 319

Probiotics, for allergy prevention, 219–220, 241

Prodrugs, corticosteroid, 475–476

Prohevein, in latex allergy, 399

Propranolol, asthma induced by, 180–183

Prostaglandin(s)
as asthma triggers, 172–173
in food allergy, 271

Prostaglandin endoperoxide H synthase, in asthma, 633–634

Protein(s), occupational asthma due to, 159–160, 195–197

Protein binding, of inhaled corticosteroids, 480–481

Protein enterocolitis, dietary, 377–379

Proton pump inhibitors, for GERD
asthma outcome and, 137–138, 142
diagnostic use of, 141

Pseudoephedrine, for allergic rhinitis, 292

Pseudomonas aeruginosa, in rhinosinusitis, 319–320

Psychiatric disorders
corticosteroid-induced, 565

in pediatric patients, atopic disorders with, **407–420**
anxiety disorders, 407–412, 415–416
attention deficit hyperactivity disorder, 407–408, 414–416
clinical implications of, 415–416
depression, 407–408, 412–416

Psychologic adjustment, asthma effects on, 84

Psychosocial aspects, of allergic rhinitis, 284–285

Psychosomatic disease, asthma as, 83, 87–88

Pulmonary function testing, in asthma
exercise-induced, 35
occupational, 200
tobacco-smoke–induced, 23

Q

Quality of life, with allergic rhinitis, 284–285

Questionnaires, for asthma treatment adherence study, **107–130**

R

Rabeprazole, for GERD, asthma outcome and, 142

Radioallergosorbent test, in food allergy, 381

Radiography, in rhinosinusitis, 321–322

Ranitidine
for GERD, asthma outcome and, 139, 142–143
for urticaria, 362

RANTES, corticosteroid effects on, 491–492

Rat allergens, in asthma, 6

Reactive airway dysfunction syndrome, occupational, 195, 198

Reflex(es)
local axonal, in gastroesophageal reflux–triggered asthma, 135
naso-pharyngo-bronchial, in asthma, 73–74
vagal, in gastroesophageal reflux–triggered asthma, 135

Reflux, gastroesophageal. *See* Gastroesophageal reflux disease.

Respiratory infections
asthma in. *See* Infections, asthma in.
in hygiene hypothesis, 222–223, 250, 252
versus allergic rhinoconjunctivitis, 269–270

Respiratory syncytial virus infections
asthma in, 47, 49, 52–53
in hygiene hypothesis, 251–252

Respiratory system, food hypersensitivity reactions in, 375

Rhinitis
allergic. *See* Allergic rhinitis.
food-induced, 151
idiopathic, versus allergic rhinitis, 269
vasomotor, versus allergic rhinitis, 269

Rhinitis medicamentosa, versus allergic rhinoconjunctivitis, 270

Rhinoconjunctivitis
allergic
corticosteroids for, 560, 567
in pediatric patients, **263–281**
age of presentation of, 264–265
common sensitizers in, 266–268
comorbid conditions with, 275
definition of, 263–264
epidemiology of, 264–265
hygiene hypothesis and, 273–275
prognosis for, 276
risk factors for, 270–273
seasonal distribution of, 266–268
nonallergic, pediatric, differential diagnosis of, 268–270

Rhinomanometry, in aspirin-induced asthma, 176

Rhinosinusitis, **67–82**
corticosteroids for, 495–499
definition of, 67, 77–78
development of, mechanisms for, 69–70
diagnosis of, 68–69, 320–323
in pediatric patients, **313–332**
anatomic considerations in, 314
asthma with
as single disease, 76–77
evidence for, 70–73
mechanisms for, 73–76
causes of, 315–319
chronic, 329
classification of, 314
complications of, 328–329
definitions of, 313–314
diagnosis of, 320–323
epidemiology of, 313

microbiology of, 319–320
pathophysiology of, 314–315
treatment of, 323–327
organisms causing, 68–69
treatment of
in pediatric patients, 323–327
medical, 71–72
surgical, 72–73

Rhinovirus infections, asthma in, 47–48, 50

Ribavirin, for respiratory infections, in asthma prevention, 59

Rimantadine, for respiratory infections, in asthma prevention, 59

Rimexolone, for allergic conjunctivitis, 567

Rodent allergens, in asthma, 6

Rofecoxib, asthma induced by, 177, 179

Roflumilast, for exercise-induced asthma, 40

Rubber elongation factor, in latex allergy, 400

Rubella, in hygiene hypothesis, 250

Rural environment, rhinoconjunctivitis and, 272

S

Salmeterol, for asthma
exercise-induced, 37–38
pharmacogenomics of, 727–731
with corticosteroids, 604–606

Schistosomiasis, in hygiene hypothesis, 255

Sedation, in allergic rhinitis and treatment, 301–310

Selye, Hans, on stress and disease, 84–85

Sensitization
in asthma, age and gender considerations in, 626, 628
in atopic march, 234–235

Separation anxiety disorder, atopic disorders with, 409–411

Shellfish allergy, asthma in, 159

Single nucleotide polymorphisms, in asthma, 724–726
coding, 724
genome-wide association studies of, 751–753
in *ADAM33* gene, 655–657, 661; 690–692
in candidate gene analysis, 686
in *CD14* gene, 716
in *HLA-G* gene, 671–672, 676
synonymous, 724

Sinusitis. *See* Rhinosinusitis.

Skin, hydration of, for atopic dermatitis, 337–338

Skin disorders. *See also* Dermatitis.
corticosteroids for
systemic, 562
topical, 569–570
application of, 571, 573
efficacy of, 573–574
indications for, 572–573
local adverse effects of, 574–578
versus systemic corticosteroids, 570–571
dryness, atopic dermatitis in, 335
in food hypersensitivity reactions, 375

Skin tests
in allergic rhinitis, 286
in anaphylaxis, 393
in asthma
food-induced, 161–162
occupational, 199–200
in food allergy, 380–381
in oral allergy syndrome, 152
in stinging insect venom allergy, 394
of neonates, 218–219

Sleep loss, in allergic rhinitis, 302

Smoke
asthma due to, 464
atopy development and, 224–225
environmental, asthma induced by, 22–25
rhinoconjunctivitis development and, 275

Smooth muscle, *ADAM33* gene expression in, 659–661

Social phobia, atopic disorders with, 409–410

Socioeconomic status
asthma and, stress impact on, 91–92
rhinoconjunctivitis and, 272–273

Sodium cromoglycate, for asthma, 603

Solar urticaria, 357

Soy protein, hypersensitivity to, 377–379

Spina bifida, latex allergy in, 397–401

Spirometry, in exercise-induced asthma, 35

Sports, asthma induced by. *See* Exercise-induced asthma.

Stanozolol, for angioedema, 363

Staphylococcus aureus
colonization by, in atopic dermatitis, 335–336, 339–340, 344
in rhinosinusitis, 319

Stasis dermatitis, topical corticosteroids for, 573

STAT genes, in asthma, 697–698

Steroid phobia, 571, 583–584, 591–593

Steroid psychosis, 565

Steroid withdrawal syndrome, 559, 561

Stevens-Johnson syndrome, corticosteroids for, 563

Stinging insects
anaphylaxis due to, 393–394
immunotherapy for, 423, 428–429

Strachan hygiene hypothesis. *See* Hygiene hypothesis.

Streptococcus pneumoniae, in rhinosinusitis, 319, 324–325

Stress, **83–105**
asthma in
caregiver stress and, 93–96
community factors in, 91–93
comorbid conditions and, 96–97
concept of, 84–85
evidence for, 87–91
family dysfunction and, 93
fatal, 97–98
neighborhood factors in, 91–93
psychologic adjustment impact of, 84
socioeconomic status and, 91–93
definition of, 85
management of, 90–91
measurement of, 85–86
pathways between illness and, 86–87

Substance P, angiotensin-converting enzyme inhibitors action on, 184

Sulfites, asthma induced by, 155–156

Superantigen toxins, secretion of, in atopic dermatitis, 336

Surgery, for rhinosinusitis, 327

Systemic corticosteroids
adverse effects of, 503–504, 563–566
allergy to, 565–566
for allergic rhinitis, 494–495
for eye disorders, 562–563
for otitis media, 499–502
for rhinosinusitis, 497
for skin disorders, 562
versus topical corticosteroids, 570–571
safety of, 503–504

T

T lymphocytes
in atopic dermatitis, 334–335
in immune response, ontogeny of, 215, 218–219

T regulatory cells, in hygiene hypothesis, 256–258

Tachyphylaxis, in topical corticosteroid use, 573

Tacrolimus, for atopic dermatitis, 340–343

TARC (thymus- and activation-regulated chemokine), in atopic dermatitis, 335

Tartrazine, asthma induced by, 157

Theophylline
for asthma
exercise-induced, 37
in combination therapy, 606
mild persistent, 602–603
gastroesophageal reflux due to, asthma in, 134

Thromboxanes, as asthma triggers, 172–173

Thymus- and activation-regulated chemokine (TARC), in atopic dermatitis, 335

Thyroid autoantibodies, in urticaria, 358

Tiotropium, for exercise-induced asthma, 37

Toll-like receptors
in asthma, 692–695
in hygiene hypothesis, 256

Toluene diisocyanate, occupational asthma due to, 197

Topical corticosteroids. *See also* Intranasal corticosteroids.
absorption of, 525
adherence to, barriers to, 586
adverse effects of, 569, 574–578
benefit versus risk of, 524–525
for eye disorders, 566–567
for skin disorders, 566, 569–570
application of, 571, 573
efficacy of, 573–574
indications for, 572–573
local adverse effects of, 574–578
versus systemic corticosteroids, 570–571

hypothalamic-pituitary-adrenal axis
effects of, 549–551
mechanism of action of, 566, 570
potency of, 568–569
precautions with, 569

Toxins, secretion of, in atopic dermatitis, 336

Toxoplasmosis, in hygiene hypothesis, 223, 251–252

Transcription factors, glucocorticoid receptor interaction with, 459, 463

Transillumination, in rhinosinusitis, 321

Treadmill test, in exercise-induced asthma, 35–36

Tree pollens, rhinoconjunctivitis due to, 266–268

Triamcinolone acetonide
for asthma
exercise-induced, 37
pharmacogenomics of, 734–737
inhaled
chemical structure of, 471
hypothalamic-pituitary-adrenal axis
effects of, 544
pharmacokinetics of, 480, 533
potency of, 474
protein binding of, 480
pulmonary deposition in, 478
receptor affinity of, 474
intranasal
for allergic rhinitis, 490
glaucoma due to, 503
hypothalamic-pituitary-adrenal axis
effects of, 549–550
topical, potency of, 568–569

Triggers, asthma. *See* Asthma, triggers of.

Trimellitic anhydride, occupational asthma due to, 197

Tropomyosins, as dust mite allergens, 2–4

Tuberculosis, in hygiene hypothesis, 249–251

Tumor necrosis factor-α, in asthma, rhinosinusitis and, 69–70

Twin studies, of allergic diseases, 215–216

U

Ultrasonography, in rhinosinusitis, 323

Urban environment, rhinoconjunctivitis and, 272

Urticaria, in pediatric patients, **353–367**
acute, 354, 357, 360
aquagenic, 357
autoimmune, 355, 358, 360–361
causes of, 357–359
cholinergic, 356–357
chronic, 354
classification of, 356–358
cold, 357
definition of, 354
delayed-pressure, 357
differential diagnosis of, 359–360
epidemiology of, 354
evaluation of, 360–361
immune-mediated, 354–355
mechanisms of, 354–355
non–immune-mediated, 354–355
pathogenesis of, 354–356
physical, 356–357
solar, 357
treatment of, 361–363

Urticaria pigmentosa, 359–360

Uveitis, corticosteroids for, 563

V

Vaccinations
for respiratory infections, in asthma prevention, 58–59
in hygiene hypothesis, 223–224, 255

Vagal reflex, in gastroesophageal reflux–triggered asthma, 135

Varicella, in hygiene hypothesis, 250

Vasoconstrictor assay, for corticosteroid potency evaluation, 566

Vasomotor rhinitis, versus allergic rhinitis, 269

Venom, of stinging insects
anaphylaxis due to, 393–394
immunotherapy for, 423, 428–429

Ventilation, increased, in gastroesophageal reflux–triggered asthma, 136

Violence, in community, stress related to, asthma and, 92

Vitamin C, for asthma
food-induced, 158–159
tobacco-smoke–induced, 26

Vitamin E, for asthma
food-induced, 159
tobacco-smoke–induced, 26

Vocal cord dysfunction
exercise-induced, 39–40
occupational, 201

W

Warm-up routines, for exercise-induced asthma, 36

Wasp stings, anaphylaxis due to, 393–394

Weed pollens, rhinoconjunctivitis due to, 266–268

Western Red Cedar, occupational asthma due to, 194

Wheat, occupational asthma due to, 159–160

Wheezing, atopic march and, 236–237

Withdrawal, from corticosteroids, 559, 561

World Health Organization, Allergic Rhinitis and its Impact Working Group of, description of, 599–601, 607–609

Y

Yellow jacket stings, anaphylaxis due to, 393–394

Z

Zafirlukast, for asthma
- exercise-induced, 37
- in combination therapy, 606
- mild persistent, 603
- pharmacogenomics of, 732–734

Zanamivir, for respiratory infections, in asthma prevention, 59

Zileuton, for asthma
- in combination therapy, 606
- mild persistent, 603
- pharmacogenomics of, 732–734